---
audienceLevel: patient
cancerTypes:
- lung
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Entrectinib - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/entrectinib
version: v1
---

# Entrectinib - NCI

# Entrectinib

Placeholder slot

(en-TREK-tih-nib)

This page contains brief information about entrectinib
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Rozlytrek

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7c71b0c-2549-4495-86b6-c2807fa54908&audience=consumer)

## Use in Cancer

Entrectinib
is approved to treat:

- **[Non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English)** that is *[ROS1](/Common/PopUps/popDefinition.aspx?id=779660&version=Patient&language=English)* [positive](/Common/PopUps/popDefinition.aspx?id=44710&version=Patient&language=English). It is used in adults whose cancer has spread to other parts of the body.
- **[Solid tumors](/Common/PopUps/popDefinition.aspx?id=45301&version=Patient&language=English)** that have an *NTRK* [gene fusion](/Common/PopUps/popDefinition.aspx?id=796818&version=Patient&language=English) without a [drug-resistance](/Common/PopUps/popDefinition.aspx?id=416100&version=Patient&language=English) [mutation](/Common/PopUps/popDefinition.aspx?id=46063&version=Patient&language=English) in certain [TRK proteins](/Common/PopUps/popDefinition.aspx?id=796814&version=Patient&language=English). It is used in adults and in children aged 1 month and older whose cancer has spread to other parts of the body or cannot be removed by surgery and has gotten worse after other treatment or cannot be treated with other therapies.¹

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that entrectinib provides a clinical benefit in these patients.

Entrectinib
is also being studied in the treatment of other types of
cancer.

## More About Entrectinib

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/759586) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Entrectinib](https://medlineplus.gov/druginfo/meds/a619049.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Entrectinib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C114984) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
